Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for awake bruxism associated with anxiety
RBR-37yq8r6Phase 3Recruiting
- Sponsor
- Universidade Federal do Paraná
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of buspirone in Awake Bruxism (AB), temporomandibular disorder (TMD) and anxiety disorder (3 arms), sponsored by Universidade Federal do Paraná. Primary endpoints: Frequency of awake bruxism and Electromyography assessment of bruxism. Started Nov 2021; status: recruiting.
02
Drugs
buspirone
03
Conditions
Awake Bruxism (AB)temporomandibular disorder (TMD)anxiety disorder
Beyond the preview
Go deeper on RBR-37yq8r6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-37yq8r6.